Enlivex Therapeutics (NASDAQ:ENLV) Stock Price Up 1.9% – Time to Buy?

Enlivex Therapeutics Ltd. (NASDAQ:ENLV)’s stock price traded up 1.9% on Wednesday . The stock traded as high as $1.14 and last traded at $1.10. 53,853 shares were traded during trading, a decline of 23% from the average session volume of 70,350 shares. The stock had previously closed at $1.08.

Analyst Ratings Changes

Separately, D. Boral Capital reissued a “buy” rating and set a $13.00 target price on shares of Enlivex Therapeutics in a research note on Wednesday, December 11th.

Enlivex Therapeutics Stock Up 1.9 %

The company has a market capitalization of $23.55 million, a P/E ratio of -1.12 and a beta of 0.99. The business has a fifty day moving average price of $1.18 and a 200 day moving average price of $1.29.

Enlivex Therapeutics (NASDAQ:ENLV) last released its earnings results on Friday, November 29th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.04. As a group, equities analysts forecast that Enlivex Therapeutics Ltd. will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Enlivex Therapeutics

An institutional investor recently bought a new position in Enlivex Therapeutics stock. Sigma Investment Counselors Inc. purchased a new position in shares of Enlivex Therapeutics Ltd. (NASDAQ:ENLV) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 30,000 shares of the company’s stock, valued at approximately $50,000. Sigma Investment Counselors Inc. owned 0.14% of Enlivex Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.